Get the Stockscreener App
23.55
2.61%
-0.63
After Hours:
23.56
0.010
+0.04%
Arcus Biosciences Inc stock is traded at $23.55, with a volume of 694.95K.
It is down -2.61% in the last 24 hours and down -0.97% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$24.18
Open:
$23.8
24h Volume:
694.95K
Relative Volume:
0.60
Market Cap:
$2.96B
Revenue:
$236.00M
Net Income/Loss:
$-369.00M
P/E Ratio:
-7.3991
EPS:
-3.1828
Net Cash Flow:
$-489.00M
1W Performance:
-0.38%
1M Performance:
-0.97%
6M Performance:
+6.08%
1Y Performance:
+159.08%
1-Day Range:
$23.31
$24.45
1-Week Range:
$21.84
$24.64
52-Week Range:
$7.91
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
23.55 | 3.04B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options - Stock Titan
Arcus Biosciences (RCUS) grants director RSUs and stock options - Stock Titan
Arcus Biosciences (RCUS) director receives RSU and stock option awards - Stock Titan
Arcus Biosciences counsel exercises 34,090 options | RCUS Insider Trading - Stock Titan
Director David L. Lacey receives RCUS stock awards at Arcus Biosciences (RCUS) - Stock Titan
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences (RCUS) director Antoni Ribas receives RSU and option awards - Stock Titan
Arcus Biosciences (RCUS) director receives new RSU and stock option grants - Stock Titan
Arcus Biosciences (NYSE: RCUS) reports 2026 shareholder vote results - Stock Titan
Arcus Biosciences Jumps 6.9% Amid Sector-Wide Rally - AlphaStreet
Arcus Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus Biosciences Drops 7.0% After LifeSci Capital Initiates at Outperform - AlphaStreet
What Did Arcus Biosciences Highlight at the Goldman Sachs Healthcare Conference - Kavout
New hire at Arcus Biosciences gets stock options and RSUs - Stock Titan
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow (NYSE:RCUS) 2026-06-09 - Seeking Alpha
Arcus Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcus, Bristol Myers team up to advance kidney cancer study - MSN
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $36.73, Implies 58% Upside - TradingView
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
(RCUS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness - Sahm
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Biosciences (RCUS) Earnings Date and Reports 2026 - MarketBeat
Arcus Biosciences Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
RCUS Initiated Coverage by LifeSci Capital -- Rating Set to Outp - GuruFocus
Lifesci Capital Initiates Coverage on Arcus Biosciences (NYSE:RCUS) - MarketBeat
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating - Moomoo
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment - marketscreener.com
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial - marketscreener.com
New drug combo from Arcus and BMS targets advanced kidney cancer - Stock Titan
Arcus Biosciences Drops 6.0% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences chief accounting officer sells $66,023 in stock By Investing.com - Investing.com South Africa
Arcus Biosciences chief accounting officer sells $66,023 in stock - Investing.com
Arcus Biosciences (RCUS) CAO 10b5-1 sale of 2,562 shares - Stock Titan
[144] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences (RCUS) Surges 3.6%: Can the Breakout Hold Above Key Resistance?getLinesFromResByArray error: size == 0 - The League of Women Voters of Texas
Biotech Catalysts Put Three Small Caps On Watch - Kalkine Media
RCUS Stock Price, Quote & Chart | ARCUS BIOSCIENCES INC (NYSE:RCUS) - ChartMill
Arcus Biosciences joins Goldman Sachs chat, offers live webcast June 9 - Stock Titan
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Liquidity Mapping Around (RCUS) Price Events - Stock Traders Daily
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences (RCUS) Insider Trading Activity 2026 - MarketBeat
Truist Financial Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $35 - Moomoo
RCUS Assumes Buy by Truist Securities -- Price Target Raised to $35 - GuruFocus
Arcus Biosciences Coverage Assumed by Truist Securities at Buy - Moomoo
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):